NanoViricides Achieves Complete Survival of Animals Infected with RSV Through NV-387 Oral Treatment
NanoViricides, a global leader in broad-spectrum antiviral nanomedicines, has announced a groundbreaking development in the treatment of respiratory syncytial virus (RSV). The company’s antiviral drug candidate, NV-387, has demonstrated strong antiviral activity against RSV/A2, resulting in the complete survival of lethally infected animals. In a recent study, extended dosing of NV-387 administered orally was compared…